Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.

ABSTRACT:

Background

Clinical data identified an association between the use of HMG-CoA reductase inhibitors (statins) and incident diabetes in patients with underlying diabetes risk factors such as obesity, hypertension and dyslipidemia. The molecular mechanisms however are unknown.

Methods

An observational cross-sectional study included 910 severely obese patients, mean (SD) body mass index (BMI) 46.7 (8.7), treated with or without statins (ABOS cohort: a biological atlas of severe obesity). Data and sample collection took place in France between 2006 and 2016. Transcriptomic signatures of statin treatment in human liver obtained from genome-wide transcriptomic profiling of five different statin drugs using microarrays were correlated to clinico-biological phenotypes and also assign

SUBMITTER: Margerie D 

PROVIDER: S-EPMC6545676 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature